Jaguar Health Portfolio Company Napo Pharmaceuticals Provides Its Novel Crofelemer Powder To Treat Intestinal Failure From Microvillus Inclusion Disease In The EU For Compassionate Use
As announced, Napo has previously provided crofelemer powder for oral solution to treat select infant and pediatric IF patients with MVID in relevant expanded access programs in the U.S. under Single-Patient
A company owned by Jaguar Health is giving a special medicine to sick kids in Europe who can't absorb food properly, through a program that lets doctors try new treatments before full approval. This shows the medicine might help real patients, which is something to watch as the company works toward bigger approvals.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.